Covalon Technologies (CVE:COV) Sets New 12-Month Low - Should You Sell?

Key Points

• Covalon Technologies reached a new 52-week low, trading at C$2.10, down from a previous close of C$2.18.
• The company's financial metrics include a debt-to-equity ratio of 3.28 and a market capitalization of C$57.03 million.
• Covalon specializes in medical products for infection management and advanced wound care, catering to various international markets.

Shares of Covalon Technologies Ltd. (CVE:COV - ) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as C$2.10 and last traded at C$2.10, with a volume of 21638 shares trading hands. The stock had previously closed at C$2.18.

Covalon Technologies Stock Performance

The company has a debt-to-equity ratio of 3.28, a current ratio of 7.27 and a quick ratio of 6.45. The business has a 50-day simple moving average of C$2.28 and a 200-day simple moving average of C$2.40. The firm has a market capitalization of C$57.03 million, a PE ratio of 23.11 and a beta of 0.44.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.